Roche Holding AG

ROG.SW

ROG.SWRoche Holding AG CH flag

Swiss Exchange

256.80

CHF

-6.20

(-2.36%)

10.31EPS

24.91P/E

207.09BMarket Cap

Jul 24Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CH0012032048

CUSIP

H69293217

Return %

Stock

S&P500

1.86

12.07

-21.34

62.30

-23.78

98.08

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y
Revenue per Share	53.65	55.17	55.9	56.57	59.36	62.48	66.56	71.81	68.21	73.88	82.27	75.65	- -
Basic EPS, GAAP	11.12	13.17	10.99	10.41	11.24	10.12	12.3	15.77	16.72	16.39	15.53	14.39	- -
Free Cash Flow per Basic Share	14.86	15.23	14.84	13.09	11.57	16.19	17.63	20.43	13.89	19.33	16.56	14.33	- -
Dividend per Share	6.94	7.5	7.91	8.17	8.26	8.37	8.49	8.7	9.01	9.14	9.31	9.5	- -
Book Value per Share	23.82	30.43	30.99	33.78	36.68	39.19	41.09	47.53	53.49	40.38	48.8	53.13	- -
Tangible Book Value per Share	5.96	11.97	-1.38	-1.93	3.61	12.38	14.14	17.31	21.65	6.38	14.39	11.32	- -
Basic Weighted Avg Shares	848	848	849	851	852	853	854	856	855	850	800	799	- -
Sales/Revenue/Turnover	45,499	46,780	47,462	48,145	50,576	53,299	56,846	61,466	58,323	62,801	65,814	60,441	62,395
Operating Margin (%)	31.04	35.01	29.69	28.71	27.82	24.4	25.98	28.55	31.79	28.91	26.55	25.47	21.5
Depreciation Expense	2,421	2,381	2,623	3,640	3,941	3,887	3,586	4,292	4,558	4,443	3,844	3,464	3,423
Net Income, GAAP	9,427	11,164	9,332	8,863	9,576	8,633	10,500	13,497	14,295	13,930	12,421	11,498	8,277
Effective Tax Rate (%)	20.55	22.51	23.81	24.45	25.17	27.95	23.2	15.08	16.13	14.16	17.13	12.22	22.1
Profit Margin (%)	20.72	23.86	19.66	18.41	18.93	16.2	18.47	21.96	24.51	22.18	18.87	19.02	13.27
Working Capital	11,162	13,404	8,006	4,414	6,070	9,412	9,211	7,135	7,541	-2,789	6,577	8,622	13,013
LT Debt	17,860	16,423	19,347	17,100	16,992	15,839	16,077	13,547	11,096	17,101	22,282	26,092	32,097
Total Equity	16,750	21,241	21,558	23,300	26,402	29,007	30,366	35,867	39,773	28,345	32,015	33,263	36,161
Return on Invested Capital (%)	25.81	29.84	23.5	21.12	20.95	18.26	21.79	27.59	27.28	25.4	23.07	21.1	14.73
Return on Capital (%)	22.44	25.66	19.97	17.56	18.36	16.19	19.23	23.38	22.57	19.64	16.93	15.69	10.45
Return on Common Equity (%)	50.08	48.53	35.81	32.19	31.92	26.7	30.65	35.62	33.08	34.8	33.86	28.22	19.16

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	2.91%	0.49%	3.23%
Net Income, GAAP	0.04%	-8.58%	-28.01%
Free Cash Flow	4.73%	1.01%	31.79%
Total Cash Common Dividend	1.33%	0.57%	0.79%
Total Equity	6.18%	1.54%	8.71%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Thomas Schinecker
Full Time Employees: 103,249
Sector: Healthcare
Industry: Drug Manufacturers - General
Address: Konzern Hauptsitz Basel Switzerland 4070
IPO Date: Aug 3, 1995
Website: roche.com
Similar Companies: GlaxoSmithKline plc (GSK.SW)
GSK plc (GLAXF)
Tong Ren Tang Technologies Co. Ltd. (1666.HK)
Daiichi Sankyo Company, Limited (DSKYF)
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (600671.SS)
Business: Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.


No results.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y
Revenue per Share	53.65	55.17	55.9	56.57	59.36	62.48	66.56	71.81	68.21	73.88	82.27	75.65	- -
Basic EPS, GAAP	11.12	13.17	10.99	10.41	11.24	10.12	12.3	15.77	16.72	16.39	15.53	14.39	- -
Free Cash Flow per Basic Share	14.86	15.23	14.84	13.09	11.57	16.19	17.63	20.43	13.89	19.33	16.56	14.33	- -
Dividend per Share	6.94	7.5	7.91	8.17	8.26	8.37	8.49	8.7	9.01	9.14	9.31	9.5	- -
Book Value per Share	23.82	30.43	30.99	33.78	36.68	39.19	41.09	47.53	53.49	40.38	48.8	53.13	- -
Tangible Book Value per Share	5.96	11.97	-1.38	-1.93	3.61	12.38	14.14	17.31	21.65	6.38	14.39	11.32	- -
Basic Weighted Avg Shares	848	848	849	851	852	853	854	856	855	850	800	799	- -
Sales/Revenue/Turnover	45,499	46,780	47,462	48,145	50,576	53,299	56,846	61,466	58,323	62,801	65,814	60,441	62,395
Operating Margin (%)	31.04	35.01	29.69	28.71	27.82	24.4	25.98	28.55	31.79	28.91	26.55	25.47	21.5
Depreciation Expense	2,421	2,381	2,623	3,640	3,941	3,887	3,586	4,292	4,558	4,443	3,844	3,464	3,423
Net Income, GAAP	9,427	11,164	9,332	8,863	9,576	8,633	10,500	13,497	14,295	13,930	12,421	11,498	8,277
Effective Tax Rate (%)	20.55	22.51	23.81	24.45	25.17	27.95	23.2	15.08	16.13	14.16	17.13	12.22	22.1
Profit Margin (%)	20.72	23.86	19.66	18.41	18.93	16.2	18.47	21.96	24.51	22.18	18.87	19.02	13.27
Working Capital	11,162	13,404	8,006	4,414	6,070	9,412	9,211	7,135	7,541	-2,789	6,577	8,622	13,013
LT Debt	17,860	16,423	19,347	17,100	16,992	15,839	16,077	13,547	11,096	17,101	22,282	26,092	32,097
Total Equity	16,750	21,241	21,558	23,300	26,402	29,007	30,366	35,867	39,773	28,345	32,015	33,263	36,161
Return on Invested Capital (%)	25.81	29.84	23.5	21.12	20.95	18.26	21.79	27.59	27.28	25.4	23.07	21.1	14.73
Return on Capital (%)	22.44	25.66	19.97	17.56	18.36	16.19	19.23	23.38	22.57	19.64	16.93	15.69	10.45
Return on Common Equity (%)	50.08	48.53	35.81	32.19	31.92	26.7	30.65	35.62	33.08	34.8	33.86	28.22	19.16

Roche Holding AG

Growth Rates

(avg. rate of change)

Company Description

Capital Structure

Working Capital

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Year	Q1	Q2	Q3	Q4	FY
2022	- -	- -	- -	- -	65,814
2023	- -	- -	- -	- -	60,441
2024	- -	- -	- -	- -	62,395